SCHEMBL5129136

SCHEMBL5129136

Cc1csc2nc(-c3ccccn3)nc(NCc3ccc(Cl)c(Cl)c3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.49
HIF1A Q16665 8/20 0.47
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TGFBR1 P36897 1/20 0.42
PDE5A O76074 1/20 0.42
METAP2 P50579 2/20 0.41
METAP1 P53582 2/20 0.41
USP1 O94782 1/20 0.40
WDR48 Q8TAF3 1/20 0.40
GPR39 O43194 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129540 0.90 PDE5A (0.46) ESR1HIF1APDE5A
SCHEMBL5122486 0.87 ESR1 (0.48) ESR1TGFBR1
SCHEMBL7512225 0.87 NPC1 (0.44) ESR1HIF1ANPC1RAB9ASMN1; SMN2
SCHEMBL5122136 0.87 NPC1 (0.57) ESR1HIF1ANPC1RAB9ASMN1; SMN2
SCHEMBL5118328 0.86 ESR1 (0.50) ESR1HIF1ANPC1MEN1KMT2A
SCHEMBL5123277 0.85 HIF1A (0.46) ESR1HIF1ANPC1RAB9AMEN1
SCHEMBL5129883 0.85 KDM4E (0.52) ESR1HIF1ANPC1RAB9AMEN1
SCHEMBL5121313 0.84 HIF1A (0.45) HIF1ANPC1HPGDMEN1KMT2A
SCHEMBL5119994 0.84 HIF1A (0.45) HIF1ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL5814533 0.84 NPC1 (0.43) ESR1HIF1ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ESR1 2256/4885HIF1A 2022/4885NPC1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.